741 results about "Combination Medication" patented technology

Controlled quantities of powdered medication are formed in controlled release packages using electrostating metering. Also provided are combination medication therapy delivery packages comprising two or more active pharmaceuticals segregated from one another in a single delivery package.

This patent is an evolution of previous combination medication patents. Previous combination patents such as U.S. Pat. No. 6,613,354 which is a combination of an NSAID and Proton Pump Inhibitor. Thus the previous patents have covered gastrointestinal prophylaxis but none has covered both gastrointestinal and cardiovascular prophylaxis. This is likely because the cardiovascular side effects of NSAIDs were only recently discovered. This patent thus represents a leap in safety in a class of medication that is used by millions of Americans on a daily basis. This combination would thus decrease morbidity and mortality.

The invention relates to an inhalation spray of antivirus medicines. The inhalation spray comprises the following components in percentage by mass of 0%-30% of antivirus activity agents, 0%-30% of auxiliary agents, 0%-30% of taste masking agents and the balance solvents, wherein the content of the antivirus activity agents and the content of the auxiliary agents are not 0% at the same time. Compared with the prior art, the inhalation spray disclosed by the application has the purpose that during outbreak period of epidemic corona viruses and other viruses, people do not need to occupy medicalresources in short supply and only need to inhale the antivirus medicines into respiratory tracts, medicine administration is accurately targeted, and the objective of preventing virus infection and propagation can be achieved; in addition, through united medication of the antivirus activity agents and the auxiliary agents, besides, various medicines are inhaled into the respiratory tract of a patient, synergistic treatment effects are generated, the viruses are eliminated, and serious respiratory tract and infection and serious pulmonary infection caused by the viruses can be treated; and chloroquine type antivirus medicines and macrocyclic antibiotics are inhaled through spraying for united medication, and the dosage of the medicines can be notably reduced, so that side effects of prolonged QT intervals, Tdp and sudden cardiac death caused by the medicines can be reduced.

A combination medication diluting and infuser device in the form of an enteral irrigation syringe having an open-mouthed barrel portion with a piston positioned in the barrel wherein the open mouth of the barrel portion is provided with a replaceable sealing cap and wherein the barrel portion provides a medication-diluting chamber when medication and diluting fluid is introduced into the chamber via the open mouth thereof and can be mixed in the diluting chamber prior to infusing the diluted medication into the patient via a top opening provided in the sealing cap.

This invention relates to a method of treating otitis externa using a topical combination medication, including one or more antifungal agent such as, for example fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, caspofungin, micafungin, terbinafine, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, econazole, enilaconazole, miconazole, oxiconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), nystatin, pimaricin, griseofulvin, ciclopirox, haloprogin, tolnaftate, and undecylenate and one or more antibacterial agent such as neomycin sulfate, polymyxin B sulfate, colistin sulfate, gentamycin, tobramycin, chloramphenicol, Ciprofloxacin, Ofloxacin, a penicillin compound, a cephalosporin compound, a macrolide compound, a fluoroquinolone compound, streptomycin, or kanamycin.

The invention relates to an anti-tumor drug compound and application thereof. The compound includes a glutaminase inhibitor and a tumor angiogenesis inhibitor which are used together with each other. The invention especially provides the glutaminase inhibitor as shown as formula (I) listed in a specification. The glutaminase inhibitor has an obvious inhibiting effect for glutaminase activity. The inhibition for the growth of the tumor strain can reach up to 90% or above under the condition that the dosage of the drug combination is only 1/5 of the dosage of singly used drugs, the generation of the bloods surrounding human tumors and the transfer of the tumors are obviously restrained and the corresponding side effect of the drug combination is much lower than that of single drug, so that the drug combination of the glutaminase inhibitor and the tumor angiogenesis inhibitor at a certain ratio is effective in treating tumors and the drug combination compared with the single drug has an obvious synergic effect and is an efficient low-toxicity antitumor drug combination.

The invention discloses ursolic acid saponin, a preparation method thereof and application in resisting highly pathogenic H5N1 influenza virus, and specifically relates to ursolic acid saponin compounds shown in general formula (I). A series of ursolic acid saponin is prepared from natural product ursolic acid serving as raw material by introducing an ester group into the C-28 site through structural modification at first, then introducing beta-glucosyl into the C-3 site, selectively protecting 3,6-OHs of the glucose by using BBTZ and introducing glycosyl into 2,4-OHs of the glucose. Pharmacological test shows that the ursolic acid saponin compounds have obvious inhibition effect on the invasion process of the H5N1 highly pathogenic influenza viruses on host cells and can be used as a medicament for preventing or treating the influenza viruses. The invention also discloses a pharmaceutical composition containing the ursolic acid saponin compounds and the combination of the compounds of the invention and other anti-virus medicines.

The invention belongs to the field of pharmaceutical preparations, and provides a pharmaceutical albumin nanoparticle, a preparation method and application of the nanoparticle to tumor targeting therapy. The nanoparticle is made from two types of proteins, namely avidin and albumin, encapsulating slightly-soluble antitumor drugs. The electrostatic interaction exists between avidin and albumin, and avidin in the nanoparticle can be combined with biotin. Avidin can target the nanoparticle encapsulating the drugs on a biotin enrichment part. Before the application of the nanoparticle, a biotinylated antibody is used for pre-targeting on a tumor part, and can improve the distribution of a nanoparticle preparation in the tumor part. The biotinylated antibody and the nanoparticle preparation are combined for therapy, thereby playing better antitumor effect than the effect played by the combination of a monoclonal antibody and an albumin nanoparticle without avidin.

The invention discloses an amoxicillin colistin sulphate granule and a preparation method thereof. The amoxicillin colistin sulphate granule comprises the following ingredients in parts by weight: 1-25 parts of amoxicillin, 0.5-50 parts of colistin sulphate and 50-90 parts of additives, as well as an adhesive accounting for 0.5-8 parts of the weight sum of the ingredients, and the amoxicillin colistin sulphate granule is prepared by such steps as sieving, dissolving, mixing, drying and pelletizing. The amoxicillin and colistin sulphate in the invention can be uniformly mixed, thereby improving the solubility of the product in water, reinforcing the efficacy, ensuring the treatment effect, facilitating the quick recovery of animals, guaranteeing easy storage and low by-effect and reinforcing the treatment effect by drug combination; the amoxicillin colistin sulphate granule can be not only used for treating mixed infection of pigs, but also being conveniently applied on clinic and facilitating the prevention and treatment of group animal diseases so as to alleviate animal stress reactions and reduce the labor intensity of manual drug use.

The invention provides a paclitaxel and diazepinocarbazole compound combined pharmaceutical composition, which comprises active ingredients and pharmaceutically acceptable excipients. The paclitaxel and diazepinocarbazole compound combined pharmaceutical composition is characterized in that the active ingredients are composed of gemcitabine and a diazepinocarbazole compound as shown in the formulaI or pharmaceutically acceptable salts thereof; and mass ratio of gemcitabine to the diazepinocarbazole compound or the pharmaceutically acceptable salts in the active ingredients is (2-8): 1. The pharmaceutical composition has good anticancer curative effect but low toxic or side effect. As the diazepinocarbazole compound is sensitive to gemcitabine, the diazepinocarbazole compound and gemcitabine are combined to produce a synergistic effect. Thereby, clinical dosage of capecitabine is reduced, toxic or side effect caused by large dosage of capecitabine is decreased, and safety index of clinic treatment is raised. The paclitaxel and diazepinocarbazole compound combined pharmaceutical composition has a good clinical application prospect.

The invention discloses a method for treating malignant tumors with joint medicament administration and also discloses an anti-malignant tumor medicinal composition with an antitumor activity and a low toxicity and an anti-malignant tumor medicinal preparation using the medicinal composition as an active component. The method comprises a step of jointing administrating anti-inflammatory medicaments, such as glucocorticosteroids or immunosuppressive agents or biotic agents of target cell factors and a carboxamidotriazole or derivatives or intermediates of the carboxamidotriazole as a medicamentto treat malignant tumors, wherein the anti-inflammatory medicaments have a certain regulation effect on cell factors. Tests prove that the combined medicament can increase the sensitivity of tumor cells to the carboxamidotriazole, so the combined medicament can be used as a broad-spectrum medicament for treating a plurality of malignant tumors, particularly non-small cell lung cancer, colon cancer and the like.

The invention discloses an officinal composition for lowering blood fat. Active ingredients are atorvastatin and probucol. The invention provides a better fat regulating drug for patients clinically suffering from severe lipid metabolism disorders and especially has favorable synergistic effect on patients at high liver function damaging risk level by drug combination; two kinds of drugs complement advantages so as to obviously lower the possibility of side effect occurrence because of increased amount of atorvastatin. The officinal composition for lowering blood fat is prepared from active ingredients and pharmaceutically acceptable supplementary materials, but is not limited in preparations, such as tablets, dispersible tablets, sustained release tablets and the like.

The invention relates to an anticancer medicine which is a lanosterol derivative. The compound has an anticancer effect, and can inhibit the growths of lung cancer cells, liver cells, mammary gland cells, brain cancer cells, and pancreatic cancer cells. The medicine is a compound with a general formula of (I), (II), (III), or (IV). The invention also provides an application of the compound or pharmaceutically acceptable salt thereof in preparing medicines used for treating cancers. The medicine can be used independently, and can be used in combination. Especially, the medicine can be used in combination with gemcitabine or nexavar. The medicine can be used in treating cancers such as lung cancer, liver cancer, pancreatic cancer, breast cancer, brain cancer, and the like.

The invention relates to an amlodipine series salt, which particularly comprises nicotinate, camsilate, pyroglutamate, L-aspartate, maleate and mesylate. The invention also relates to a pril compoundor a pharmaceutical composition of a medicinal salt of the pril compound and a preparation method thereof, and a drug combination medicine box containing a composition of the amlodipine series salt and a composition of sartan compounds. The composition of the invention comprises the following components: a) a certain amount of an amlodipine salt; b) a certain amount of the pril compound or a medicinal salt of the pril compound; and c) a medicinal carrier or a diluting agent. The composition or the medicine box can be used for treating the patients suffering from hypertension, angina pectoris,atherosclerosis, and/or hypersphyxia and treating the patients (including the human beings) having heart danger symptoms.

The invention discloses application of PEG-HM-3 and platinum, taxol or Emtriva medicines to preparation of solid tumor medicines, and belongs to the field of medicines for treating tumors. The PEG-HM-3 is polyethylene glycol modified polypeptide HM-3 with the molecular weight range of 10,000 to 40,000; and the platinum, taxol or Emtriva medicines serving as active components and auxiliary acceptable medicinal carriers are prepared into various pharmaceutically acceptable preparations. According to a large amount of experiments, an integrin blocking agent PEG-HM-3 has a definite target spot and is reasonably used in combination with platinum, taxol or Emtriva, so growth of tumors such as lung cancer, liver cancer, gastric cancer, breast cancer, cervical cancer, ovarian cancer and intestinal cancer can be effectively inhibited. The medicines are combined to serve as a medicine, so tumors can be treated effectively, medicine combination is scientific, reasonable, practical and effective, the treatment spectrum of tumor treatment is greatly enlarged, the toxic or side effect is reduced, and obvious social value and market value are achieved.

The invention relates to a pharmaceutical composition containing amlodipine besylate, and a statins compound or a pharmaceutically acceptable salt thereof, a preparation method and a medicine box for drug combination of the medicine composition. The composition comprises the following components: a) a certain amount of the amlodipine besylate; b) a certain amount of one or more statins compounds or pharmaceutically acceptable salts thereof; and c) a pharmaceutically acceptable carrier or a diluting agent. The composition or the medicine box can be used for treating patients suffering from angina pectoris, atherosclerosis and/or accompanied hypertension and hyperlipoidemia, and treating patients (including human beings) having heart risky symptoms.

The invention provides a drug dose prediction method and device, electronic equipment and a storage medium, is applied to the technical field of data processing, and can determine more accurate drug use doses for different patients. The method comprises the following steps: acquiring clinical original data of a target patient, wherein the clinical original data comprises demographic information, therapeutic drug use information, drug combination information, adjuvant therapy means, gene polymorphism and inspection information; performing data preprocessing on the clinical original data to obtain target feature data, the data preprocessing including at least one of data cleaning, data normalized coding and data screening; and inputting the target feature data into a drug dose prediction model to obtain the drug dose of the target patient in unit time.

The invention discloses application of chlorogenic acid in preparation of medicines for treating cardiomyopathy. The medicines have the effects of up-regulating myocardial specific expression structure genes ACTC1 and corresponding protein, down-regulating caspase-3 genes and corresponding protein thereof, and up-regulating Bc1-2 genes and corresponding protein. The invention also discloses a medicine for treating cardiomyopathy, and the medicine comprises chlorogenic acid and pharmaceutically acceptable auxiliary materials or auxiliary components. The invention also discloses a combined medicine for treating cardiomyopathy.

The invention discloses a medicament for treating coccidiosis, particularly a novel compound anti-coccidiosis medicament and a preparation method thereof. The novel compound anti-coccidiosis medicament is characterized by being prepared from the following components: decoquinate, toltrazuril, polymer carrier, solubilizing agent and anhydrous dextrose. Therefore, the medicament has the advantages that: the indissoluble decoquinate and toltrazuril are prepared into water-soluble substances by using solid dispersion technology and inclusion technology, and the decoquinate and toltrazuril are mixed to fulfill the aim of reducing dosage, improving curative effect and reducing drug resistance; moreover, the synergistic effect of the medicaments can be realized by combining the decoquinate and the toltrazuril, the killing effect is enhanced and the dosage of each medicament is reduced by half.

The invention relates to a pharmaceutical composition containing a PI3K inhibitor and a PERK inhibitor, and applications thereof in preparing anti-tumor drugs. Independent application of the PI3K inhibitor and independent application of the PERK inhibitor both possesses certain inhibition effect on growth of tumor cells; after drug combination of the PI3K inhibitor and the PERK inhibitor, the pharmaceutical composition is capable of inhibiting growth of tumor cells, inducing apoptosis, and inhibiting formation of cell colonies obviously, the effect is much better than that of independent application, and excellent synergistic effect is achieved. The toxicity of the pharmaceutical composition on human normal vascular endothelial cells is relatively low; the pharmaceutical composition possesses excellent inhibition effect on tumor cells; cancer treatment effect is promising to be improved; and the pharmaceutical composition can be used for preparing anti-tumor drugs.

The invention discloses application of cyclic dinucleotide cGAMP to prevention and treatment of tumors through drug combination, belonging to the technical field of biological medicine. The invention also discloses a plurality of drug compositions for prevention and treatment of tumors. The drug compositions for prevention and treatment of tumors are composed of cyclic dinucleotide and one selected from a group consisting of fluorouracil, cyclophosphamide, methotrexate, cisplatin, carboplatin, paclitaxel, vincristine, mitomycin, gemcitabine and actinomycin. Results of in-vivo research show that the drug compositions composed of cyclic dinucleotide and one selected from a group consisting of fluorouracil, cyclophosphamide, methotrexate, cisplatin, carboplatin, paclitaxel, vincristine, mitomycin, gemcitabine and actinomycin have obviously improved curative effect and obviously decreased toxicity.

The invention relates to polypeptide, protein or peptide-like medicine from influenza virus hemagglutinin, and a method of the polypeptide, belongs to the technical field of biological medicines, and in particular relates to eight influenza virus hemagglutinin fragment peptides which can block influenza virus infection and have the serial numbers SEQ ID NO.1 to SEQ ID NO.8. The fragment peptides can inhibit and block infection of different species and influenza viruses of different subtypes to a host, including multiple influenza virus strains such as highly pathogenic avian influenza virus, seasonal human influenza virus and the like. The invention provides the peptide sequence (including amino acid sequences of peptides and polynucleotide sequences of encoded peptides), derivative peptides (including amino acid sequences of peptides and polynucleotide sequences of encoded peptides), peptide compositions and independent or united applications of peptides in preventing or treating influenza virus, such as medicine combination of peptides provided by the invention and other anti-influenza medicines.

The invention relates to novel beta-chloroethylnitrosourea compounds, and a synthesis method and application thereof. The structure of the beta-chloroethylnitrosourea compounds is disclosed as general formula (II). The in-vitro antitumor screening test on the compounds disclosed as general formula II proves that the compounds disclosed as general formula I have obvious inhibiting action on human cerebral nerve glioma cells SF763, SF767, SF126 and SF188, human colon cancer cell HT29, mouse leukaemia cell L1210 and many other tumor cell lines and have higher tumor inhibiting activity than the existing CENU and CENU/O6-benzylguanine combined medicine.